The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men
Abstract
OBJECTIVE— Pharmacological use of peroxisome proliferator–activated receptor (PPAR)δ agonists and transgenic overexpression of PPARδ in mice suggest amelioration of features of the metabolic syndrome through enhanced fat oxidation in skeletal muscle. We hypothesize a similar mechanism operates in humans. RESEARCH DESIGN AND METHODS— The PPARδ agonist (10 mg o.d. GW501516), a comparator PPARα agonist (20 μg o.d. GW590735), and placebo were given in a double-blind, randomized, three-parallel group, 2-week study to six healthy moderately overweight subjects in each group. Metabolic evaluation was made before and after treatment including liver fat quantification, fasting blood samples, a 6-h meal tolerance test with stable isotope fatty acids, skeletal muscle biopsy for gene expression, and urinary isoprostanes for global oxidative stress. RESULTS— Treatment with GW501516 showed statistically significant reductions in fasting plasma triglycerides (−30%), apolipoprotein B (−26%), LDL cholesterol (−23%), and insulin (−11%), whereas HDL cholesterol was unchanged. A 20% reduction in liver fat content (P < 0.05) and 30% reduction in urinary isoprostanes (P = 0.01) were also observed. Except for a lowering of triglycerides (−30%, P < 0.05), none of these changes were observed in response to GW590735. The relative proportion of exhaled CO2 directly originating from the fat content of the meal was increased (P < 0.05) in response to GW501516, and skeletal muscle expression of carnitine palmitoyl-transferase 1b (CPT1b) was also significantly increased. CONCLUSIONS— The PPARδ agonist GW501516 reverses multiple abnormalities associated with the metabolic syndrome without increasing oxidative stress. The effect is probably caused by increased fat oxidation in skeletal muscle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity
Wang, Y.-X., Lee, C.-H., Tiep, S., Yu, R. T., Ham, J., Kang, H., & Evans, R. M. (2003) · Cell · doi:10.1016/s0092-8674(03)00269-1 · Cited by 1,296
Regulation of Muscle Fiber Type and Running Endurance by PPARδ
Wang, Y.-X., Zhang, C.-L., Yu, R. T., Cho, H. K., Nelson, M. C., Bayuga-Ocampo, C. R., Ham, J., Kang, H., & Evans, R. M. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020294 · Cited by 1,089
Oliver, W. R., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091021198 · Cited by 1,046
Self-citationImprovement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone
Nolan, J. J., Ludvik, B., Beerdsen, P., Joyce, M., & Olefsky, J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311803 · Cited by 926
Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306981100 · Cited by 832
Cited by
(1998) · PubMed · Cited by 2,737
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Metabolic requirements for the maintenance of self-renewing stem cells
Ito, K., & Suda, T. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3772 · Cited by 1,014
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820
PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778
A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance
Ito, K., Carracedo, A., Weiss, D., Arai, F., Ala, U., Avigan, D. E., Schafer, Z. T., Evans, R. M., Suda, T., Lee, C.-H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2882 · Cited by 729
Identification of a Physiologically Relevant Endogenous Ligand for PPARα in Liver
Chakravarthy, M. V., Lodhi, I. J., Yin, L., Malapaka, R. R. V., Xu, H. E., Turk, J., & Semenkovich, C. F. (2009) · Cell · doi:10.1016/j.cell.2009.05.036 · Cited by 533
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Rotman, Y., & Sanyal, A. J. (2017) · Gut · doi:10.1136/gutjnl-2016-312431 · Cited by 410
Thiazolidinediones and PPARγ agonists: time for a reassessment
Cariou, B., Charbonnel, B., & Staels, B. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.03.001 · Cited by 390
Pharmacological approaches to restore mitochondrial function
Andreux, P. A., Houtkooper, R. H., & Auwerx, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4023 · Cited by 383
Distinct but complementary contributions of PPAR isotypes to energy homeostasis
Dubois, V., Eeckhoute, J., Lefebvre, P., & Staels, B. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88894 · Cited by 383
Molecular pathways in non-alcoholic fatty liver disease
Auguet, T., Berlanga, A., Guiu-Jurado, E., & Porras, J. A. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s62831 · Cited by 379
PPARs: diverse regulators in energy metabolism and metabolic diseases
Wang, Y.-X. (2010) · Cell Research · doi:10.1038/cr.2010.13 · Cited by 366
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
Pharmacotherapy for NASH: Current and emerging
Konerman, M. A., Jones, J. C., & Harrison, S. A. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.015 · Cited by 292
Ali, K. M., Wonnerth, A., Huber, K., & Wojta, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02081.x · Cited by 292
Roles of PPARs in NAFLD: Potential therapeutic targets
Tailleux, A., Wouters, K., & Staels, B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.016 · Cited by 282
PPARs and nonalcoholic fatty liver disease
Liss, K. H. H., & Finck, B. N. (2017) · Biochimie · doi:10.1016/j.biochi.2016.11.009 · Cited by 275
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 264
Insulin resistance and insulin sensitizing agents
Mastrototaro, L., & Roden, M. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154892 · Cited by 254
PPAR Agonists and Metabolic Syndrome: An Established Role?
Botta, M., Audano, M., Sahebkar, A., Sirtori, C., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 253
PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Hong, F., Pan, S., Guo, Y., Xu, P., & Zhai, Y. (2019) · Molecules · doi:10.3390/molecules24142545 · Cited by 233
Physiological functions of peroxisome proliferator-activated receptor β
Neels, J. G., & Grimaldi, P. A. (2014) · Physiological Reviews · doi:10.1152/physrev.00027.2013 · Cited by 161
The Role of Mitochondria in the Pathophysiology of Skeletal Muscle Insulin Resistance
Pagel-Langenickel, I., Bao, J., Pang, L., & Sack, M. N. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0003 · Cited by 154
Christodoulides, C., Dyson, P., Sprecher, D., Tsintzas, K., & Karpe, F. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0111 · Cited by 153
Self-citationShan, W., Palkar, P. S., Murray, I. A., McDevitt, E. I., Kennett, M. J., Kang, B. H., Isom, H. C., Perdew, G. H., Gonzalez, F. J., & Peters, J. M. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn142 · Cited by 97
Coll, T., Álvarez-Guardia, D., Barroso, E., Gómez-Foix, A. M., Palomer, X., Laguna, J. C., & Vázquez-Carrera, M. (2010) · Endocrinology · doi:10.1210/en.2009-1211 · Cited by 90
Shearer, B. G., Wiethe, R. W., Ashe, A., Billin, A. N., Way, J. M., Stanley, T. B., Wagner, C. D., Xu, R. X., Leesnitzer, L. M., Merrihew, R. V., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm900464j · Cited by 78
Self-citationDwyer, M. A., Kazmin, D., Hu, P., McDonnell, D. P., & Malek, G. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0392 · Cited by 61
Metadata
- Authors
- Risérus, U., Sprecher, D., Johnson, T., Olson, E., Hirschberg, S., Liu, A., Fang, Z., Hegde, P., Richards, D., Sarov-Blat, L., Strum, J. C., Basu, S., Cheeseman, J., Fielding, B. A., Humphreys, S. M., Danoff, T., Moore, N. R., Murgatroyd, P., O'Rahilly, S., Sutton, P., Willson, T., Hassall, D., Frayn, K. N., & Karpe, F.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-02-01
- Volume
- 57
- Issue
- 2
- Pages
- 332-339
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2170075604
- Cited by
- 325
- References
- 48
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.